 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
 |
 |
 |
 |
 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
 The optimum business model for the Pharmaceuticals industry in the 21st Century is based on focussed innovation on specific diseases or on a therapeutic category, which business can be undertaken and grown, either by means of a company's own R&D programs and strategic intent, or by external means such as outward/inward corporate partnering and acquisitions. FPG advises its clients on such strategic Corporate Partnerships, Divestments and Acquisitions, as well as on creative financings, since these elements are all critical to the healthy future of pharmaceutical companies. FPG strives to balance its expertise between the rigorous mastery of transactional processes, a seasoned understanding of the industrial context, and a deep grounding in the scientific and clinical development underpinnings in these therapeutic areas:
Drug Delivery technology offers ways in which therapeutic and prophylactic compounds can be more effectively delivered, thereby enhancing patient compliance and convenience, extending the patentable life of the drug and increasing efficacy with fewer side effects. Of the numerous delivery methods available to administer drugs, FPG has extensive knowledge of most of them, such as these major modalities: > Oral Delivery (Sustained Release, Rapid Dissolve, Taste-Masking) > Intranasal > Pulmonary > Buccal > Transdermal > Injectable (Nanospheres, Polymers, Gels) Incremental Services and Smaller Transactions In order to provide its clients with incremental advisory services, FPG has developed a collaborative working relationship with bioStrategies Group, a global strategy consulting firm that works with Life Science companies to commercialize their products and technologies. The firmâs clientele ranges from some of the leading biopharmaceutical, drug discovery tool, diagnostic and medical device companies to startups seeking early stage advice. bioStrategies Groupâs approaches blend strong market research, quantitative methods, strategic frameworks and extensive industry experience to assist its clients in making key commercialization decisions. Typical strategy engagements involve research pipeline and product portfolio management, business model definition, product and clinical development strategy, market research and the related marketing plans for specific products. For smaller clients or for smaller transactions, FPG has created a stand-alone but affiliated advisory service, Capel Thompson & Homer, headed by longTerm London colleague, Paul Thompson. This separate firm specializes in European partnering transactions, interim project management, business development, product disposals/purchases and technology sales/acquisitions. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
